Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock:A randomized clinical trial

JAMA Internal Medicine

Volumn 176, Issue 9, 2016, Pages 1266-1276

  Bloos, Frank ^a   Trips, Evelyn ^b   Nierhaus, Axel ^c   Briegel, Josef ^d   Heyland, Daren K ^e   Jaschinski, Ulrich ^f   Moerer, Onnen ^g   Weyland, Andreas ^h   Marx, Gernot ⁱ   Grundling, Matthias ^j   Kluge, Stefan ^c   Kaufmann, Ines ^d   Ott, Klaus ^f   Quintel, Michael ^g   Jelschen, Florian ^h   Meybohm, Patrick ^k   Rademacher, Sibylle ^l   Meier Hellmann, Andreas ^m   Utzolino, Stefan ⁿ   Kaisers, Udo X ^o   Putensen, Christian ^p   Elke, Gunnar ^q   Ragaller, Maximilian ^r   Gerlach, Herwig ^s   Ludewig, Katrin ^a   Kiehntopf, Michael ^a   Bogatsch, Holger ^b   Engel, Christoph ^b   Brunkhorst, Frank M ^a   Loeffler, Markus ^b   Reinhart, Konrad ^a   more..

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e KINGSTON GENERAL HOSPITAL   (Canada)

^f UNIVERSITY HOSPITAL AUGSBURG   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h KLINIKUM OLDENBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^j UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m HELIOS KLINIKUM ERFURT   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^p UNIVERSITY HOSPITAL BONN   (Germany)

^q UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^r UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^s VIVANTES KLINIKUM NEUKÖLLN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; PLACEBO; PROADRENOMEDULLIN; PROCALCITONIN; SELENIUM; SODIUM CHLORIDE; SODIUM SELENITE; ANTIOXIDANT; BIOLOGICAL MARKER; CALCITONIN;

ADULT; AGED; ALGORITHM; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; FACTORIAL DESIGN; FEMALE; FOLLOW UP; GERMANY; HORMONE BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORTALITY; MORTALITY RATE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY INFECTION; SELENIUM BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; EPIDEMIOLOGY; HOSPITAL MORTALITY; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; BIOMARKERS; CALCITONIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GERMANY; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SODIUM SELENITE;

EID: 84998704918     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.2514     Document Type: Article

References (30)

1. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 2011;107(1):57-64.
2. Sakr Y, Reinhart K, Bloos F, et al. Time course and relationship between plasma selenium concentrations, systemic inflammatory response, sepsis, and multiorgan failure. Br J Anaesth. 2007; 98(6):775-784.
3. Jang JY, Shim H, Lee SH, Lee JG. Serum selenium and zinc levels in critically ill surgical patients. J Crit Care. 2014;29(2):317.e5-317.e8.
4. Manzanares W, Biestro A, Torre MH, Galusso F, Facchin G, Hardy G. High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation. Intensive Care Med. 2011;37(7):1120-1127.
5. Valenta J, Brodská H, Drabek T, Hendl J, Kazda A. High-dose selenium substitution in sepsis: a prospective randomized clinical trial. Intensive Care Med. 2011;37(5):808-815.
6. Alhazzani W, Jacobi J, Sindi A, et al. The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2013;41(6):1555-1564.
7. Angstwurm MWA, Engelmann L, Zimmermann T, et al. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med. 2007;35(1):118-126.
8. Heyland D, Muscedere J, Wischmeyer PE, et al; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients [published correction appears in N Engl J Med. 2013;368(19):1853]. N Engl J Med. 2013;368 (16):1489-1497.
9. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
10. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435.
11. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000;26(9): 1193-1200.
12. Harbarth S, Holeckova K, Froidevaux C, et al; Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396-402.
13. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25(4): 609-634.
14. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;(February): S1473-3099(16)00053-0.
15. Jensen JU, Hein L, Lundgren B, et al; Procalcitonin and Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048-2058.
16. Brunkhorst FM, Oppert M, Marx G, et al; German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012;307 (22):2390-2399.
17. Pocock SJ. Clinical Trials. Chichester, England: John Wiley&Sons; 2013.
18. Brunkhorst FM, Reinhart K. Diagnosis and causal treatment of sepsis [in German]. Internist (Berl). 2009;50(7):810-816.
19. Lan KKG, Demets D. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70 (3):659-663.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3): 549-556.
21. Heyland DK, Dhaliwal R, Suchner U, Berger MM. Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med. 2005;31(3):327-337.
22. Huang T-S, Shyu Y-C, Chen H-Y, et al. Effect of parenteral selenium supplementation in critically ill patients: a systematic review and meta-analysis. PLoS One. 2013;8(1):e54431.
23. Heyland DK, Elke G, Cook D, et al; Canadian Critical Care Trials Group. Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial. JPEN J Parenter Enteral Nutr. 2015;39(4):401-409.
24. Bouadma L, Luyt C-E, Tubach F, et al; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463-474.
25. Nobre V, Harbarth S, Graf J-D, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498-505.
26. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effectof procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066.
27. Chastre J, Wolff M, Fagon J-Y, et al; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19): 2588-2598.
28. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372 (21):1996-2005.
29. Brunkhorst FM, Engel C, Bloos F, et al; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125-139.
30. Karlsson S, Heikkinen M, Pettilä V, et al; Finnsepsis Study Group. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14(6):R205.